IPSC

Century Therapeutics, Inc. [IPSC] Stock Forecast

Q: What is Century Therapeutics, Inc. stock symbol ?

Century Therapeutics, Inc. is a US stock, located in Philadelphia of Pa and trading under the symbol IPSC

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

IPSC Stock Summary

Earnings are expected to rise 921.03% next year

The Moving Average Convergence Divergence (MACD) for IPSC recently turned positive (within last 10 days).

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

Currently unprofitable, and not expected to turn profitable in the coming year

Profit margins (-51.83%) are lower than the previous year (-25.18%)

Top 10 Correlated ETFs

IPSC

Top 10 Correlated Stocks

IPSC

In the News

12:02 10 Dec 2023 IPSC

Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study

Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.

07:30 10 Dec 2023 IPSC

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas.

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., Interim Chief Executive Officer, will participate in a fireside chat at the Chardan 7th Annual Genetic Medicines Conference on Tuesday, October 3, 2023 at 9:00 AM ET.

10:40 10 Dec 2023 IPSC

Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates

Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.53 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.66 per share a year ago.

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will participate in a fireside chat at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit on Monday, April 24, 2023 at 10:30 AM ET.

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences:

07:00 10 Dec 2023 IPSC

Century Therapeutics to Present at Upcoming Investor Conferences

PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will participate in the following investor conferences in February:

04:03 10 Dec 2023 IPSC

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

10:59 10 Dec 2023 IPSC

5 Best and Worst Performing Small-Cap Stocks in Dec 2022

Small-cap stocks usually suffer more than mid- and large-cap stocks when the market as a whole is struggling, and when the market is rallying, they could offer higher returns as well.

11:18 10 Dec 2023 IPSC

After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC)

Century Therapeutics, Inc. (IPSC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

IPSC Financial details

Company Rating

Buy

Market Cap

142.41M

Income

-128.96M

Revenue

2.49M

Book val./share

3.69

Cash/share

2.85

Dividend

Dividend %

Employees

163

Optionable

Shortable

Yes

Earnings

21 Mar 2024

P/E

-1.1

Forward P/E

-1.22

PEG

0.42

P/S

57.24

P/B

0.65

P/C

0.84

P/FCF

-1.37

Quick Ratio

8.38

Current Ratio

8.5

Debt / Equity

0.22

LT Debt / Equity

0.21

EPS (TTM)

-2.19

EPS next Y

-1.95

EPS next Q

-0.51

EPS this Y

-23.31%

EPS next Y

-10.96%

EPS next 5Y

-34.25%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

49.49%

EPS Q/Q

-1.79%

SMA20

12.18%

SMA50

-17.06%

SMA100

-42.05%

Inst Own

26.14%

Inst Trans

0.79%

ROA

-32%

ROE

-49%

ROC

-0.36%

Gross Margin

100%

Oper. Margin

-5470%

Profit Margin

-5183%

Payout

Shs Outstand

59.84M

Shs Float

24.24M

Target Price

21.25

52W Range

1.28-9.705

52W High

-73.56%

52W Low

+138%

RSI

77.2

Rel Volume

1.2

Avg Volume

147.97K

Volume

177.96K

Perf Week

67.61%

Perf Month

61.9%

Perf Quarter

-31.41%

Perf Half Y

-29.59%

Beta

0.668

Volatility

0.4%, 0.28%

Prev Close

2.15%

Price

2.38

Change

8.68%

IPSC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0.09
Net income per share	-5.91	-1.31	-2.96	-2.27
Operating cash flow per share	-0.39	-0.99	-2.75	0.24
Free cash flow per share	-0.45	-1.22	-4.14	-0.29
Cash per share	1.96	1.81	6.88	5.46
Book value per share	-2.21	-2.55	12.23	5.24
Tangible book value per share	-2.21	-2.77	12.23	5.24
Share holders equity per share	-2.21	-2.55	12.23	5.24
Interest debt per share	0	0.52	0.81	0.87
Market cap	949.92M	954.38M	513.75M	296.29M
Enterprise value	905.86M	948.72M	480.76M	261.44M
P/E ratio	-3.86	-17.46	-5.36	-2.26
Price to sales ratio	0	0	0	56.99
POCF ratio	-58.75	-23.13	-5.77	21.09
PFCF ratio	-50.99	-18.68	-3.83	-17.9
P/B Ratio	-10.34	-8.97	1.3	0.98
PTB ratio	-10.34	-8.97	1.3	0.98
EV to sales	0	0	0	50.29
Enterprise value over EBITDA	-48.77	-20.16	-5.09	-2.16
EV to operating cash flow	-56.03	-22.99	-5.4	18.6
EV to free cash flow	-48.63	-18.57	-3.59	-15.79
Earnings yield	-0.26	-0.06	-0.19	-0.44
Free cash flow yield	-0.02	-0.05	-0.26	-0.06
Debt to equity	0	-0.2	0.06	0.16
Debt to assets	0	0.2	0.06	0.1
Net debt to EBITDA	2.37	0.12	0.35	0.29
Current ratio	28.1	6.51	14.57	10.72
Interest coverage	0	-141.46	-74.42	-121.11
Income quality	0.07	0.77	0.93	-0.11
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	0	0	0	6.13
Research and developement to revenue	0	0	0	20.61
Intangibles to total assets	0	0.09	0	0
Capex to operating cash flow	0.15	0.24	0.51	-2.18
Capex to revenue	0	0	0	-5.89
Capex to depreciation	-9.88	-7.01	-12	-3.63
Stock based compensation to revenue	0	0	0	2.05
Graham number	17.14	8.65	28.53	16.35
ROIC	2.69	0.75	-0.22	-0.34
Return on tangible assets	-2.71	-0.56	-0.22	-0.27
Graham Net	-2.4	-3.25	5.61	2.29
Working capital	81.13M	66.69M	212.5M	289.9M
Tangible asset value	-91.86M	-115.8M	396.24M	302.74M
Net current asset value	-98.63M	-134.39M	187.02M	135.92M
Invested capital	0	-0.2	0.06	0.16
Average receivables	0	515.5K	579K	515K
Average payables	0	4.82M	7.84M	6.53M
Average inventory	0	2.11M	815K	-125K
Days sales outstanding	0	0	0	54.76
Days payables outstanding	0	0	0	0
Days of inventory on hand	0	0	0	0
Receivables turnover	0	0	0	6.67
Payables turnover	0	0	0	0
Inventory turnover	0	0	0	0
ROE	2.68	0.51	-0.24	-0.43
Capex per share	-0.06	-0.24	-1.39	-0.53

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.04	0.01	0.03	0	0
Net income per share	-0.53	-0.55	-0.53	-0.56	-0.55
Operating cash flow per share	-0.42	-0.4	-0.5	-0.32	-0.23
Free cash flow per share	-0.59	-0.51	-0.58	-0.4	-0.28
Cash per share	6.14	5.46	4.29	2.64	2.85
Book value per share	5.7	5.24	4.73	4.18	3.69
Tangible book value per share	5.7	5.24	4.73	4.18	3.69
Share holders equity per share	5.7	5.24	4.73	4.18	3.69
Interest debt per share	0.82	0.86	0.88	0.71	0.8
Market cap	573.36M	296.29M	203.38M	187.23M	118.9M
Enterprise value	509.28M	261.44M	168.01M	164.81M	109.12M
P/E ratio	-4.66	-2.34	-1.63	-1.41	-0.91
Price to sales ratio	257.81	568.69	118.24	1.89K	803.35
POCF ratio	-23.65	-12.93	-6.96	-9.73	-8.71
PFCF ratio	-16.84	-10.16	-5.94	-7.88	-7.03
P/B Ratio	1.74	0.98	0.73	0.76	0.54
PTB ratio	1.74	0.98	0.73	0.76	0.54
EV to sales	228.99	501.8	97.68	1.66K	737.33
Enterprise value over EBITDA	-18.42	-9.18	-5.67	-6.66	-3.88
EV to operating cash flow	-21.01	-11.41	-5.75	-8.56	-8
EV to free cash flow	-14.96	-8.96	-4.91	-6.94	-6.45
Earnings yield	-0.05	-0.11	-0.15	-0.18	-0.28
Free cash flow yield	-0.06	-0.1	-0.17	-0.13	-0.14
Debt to equity	0.14	0.16	0.19	0.17	0.22
Debt to assets	0.09	0.1	0.11	0.1	0.12
Net debt to EBITDA	2.32	1.22	1.19	0.91	0.35
Current ratio	13.44	10.72	9.24	8.42	8.5
Interest coverage	-107.22	-104.74	-79.41	-257.92	0
Income quality	0.79	0.72	0.93	0.58	0.42
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.63	15.82	5.18	83.12	60.72
Research and developement to revenue	11.64	49.11	14.48	229.57	153.97
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.4	0.27	0.17	0.23	0.24
Capex to revenue	-4.41	-12.03	-2.9	-45.45	-22.06
Capex to depreciation	-3.54	-2.21	-1.72	-1.39	-0.97
Stock based compensation to revenue	1.25	5.24	2.21	33.18	26.88
Graham number	8.24	8.04	7.53	7.27	6.76
ROIC	-0.08	-0.09	-0.09	-0.11	-0.12
Return on tangible assets	-0.06	-0.07	-0.07	-0.08	-0.08
Graham Net	3.01	2.29	1.24	-0.22	-0.14
Working capital	334.73M	289.9M	228.25M	142.12M	153.27M
Tangible asset value	330.21M	302.74M	277.18M	247.57M	219.23M
Net current asset value	180.1M	135.92M	76.88M	-8.31M	-4.62M
Invested capital	0.14	0.16	0.19	0.17	0.22
Average receivables	324K	572K	1.12M	1.59M	1.69M
Average payables	4.87M	5.57M	4.46M	3.55M	4.78M
Average inventory	0	0	-732.5K	-1.59M	-1.69M
Days sales outstanding	14.73	134.74	76.66	1.55K	1.01K
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	6.11	0.67	1.17	0.06	0.09
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.09	-0.1	-0.11	-0.13	-0.15
Capex per share	-0.17	-0.11	-0.09	-0.08	-0.05

IPSC Frequently Asked Questions

What is Century Therapeutics, Inc. stock symbol ?

Century Therapeutics, Inc. is a US stock , located in Philadelphia of Pa and trading under the symbol IPSC

Is Century Therapeutics, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $21.25. The lowest prediction is $14 and the highest is $27

What is IPSC stock prediction ?

What is Century Therapeutics, Inc. stock quote today ?

Century Therapeutics, Inc. stock price is $2.38 today.

Is Century Therapeutics, Inc. stock public?

Yes, Century Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 147.97K
Market Capitalization 142.41M
Employee 163
CEO Dr. Michael C. Diem M.D.
Headquarters Philadelphia,PA,US
IPO Date 2021-06-18
Website https://www.centurytx.com

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.